# A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

> **NCT01672775** · PHASE1 · COMPLETED · sponsor: **Agensys, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Renal Cell Carcinoma of Papillary Histology
- Renal Cell Carcinoma With Clear Cell Histology
- Renal Cell Carcinoma With Non-Clear Cell Histology

## Interventions

- **DRUG:** AGS-16C3F

## Key facts

- **NCT ID:** NCT01672775
- **Lead sponsor:** Agensys, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-18
- **Primary completion:** 2017-02-21
- **Final completion:** 2017-02-21
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01672775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01672775, "A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01672775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*